Knowledge graph · Drug
Catumaxomab
monoclonal antibody
- Identifier
- CI-DRUG-00000716
- Entity page
- /drug/catumaxomab ↗
- Edges
- 38
- Neighbours
- 13 cancers4 genes10 trials4 approvals
- Drawn
- 31 of 31 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Catumaxomab approved for …APPROVED_FORderived4 of 4 | ||||||||
| → approved for | EMA · EU · 2025Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy. EMA (EU) · approved · 2025-02-10 · Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-po… | — | approved | not mapped | 1 | Regulatory | ema | open ↗ |
| → approved for | EMA · EU · 2009 | |||||||